Evidence map›Paper›PMID 33318671›Full record

ArticleNature chemistry2021

Developing the

Tyler A Bailey, Veronika Mocko, Katherine M Shield, Dahlia D An, Andrew C Akin, Eva R Birnbaum, Mark Brugh, Jason C Cooley, Jonathan W Engle, Michael E Fassbender and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 50 citations in OpenAlex.

  1. ImprovedACS omega · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  10. Examination of the PET in vivo generatorEuropean journal of nuclear medicine and molecular imaging · 2024
    Article
  11. Article
  12. Scalability study on [EJNMMI radiopharmacy and chemistry · 2024
    Article
  13. Exploring the PET in vivo generatorbioRxiv : the preprint server for biology · 2024
    Article
  14. Review
  15. Article
  16. Review
  17. Targeted Alpha Therapy: All We Need to Know aboutPharmaceuticals (Basel, Switzerland) · 2023
    Review
  18. Review
  19. Review
  20. Development ofACS omega · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Tyler A Bailey *Department of Nuclear Engineering, University of California, Berkeley, CA, USA.
Veronika Mocko *Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID http://orcid.org/0000-0001-6041-6778
Katherine M Shield *Department of Nuclear Engineering, University of California, Berkeley, CA, USA.
Dahlia D AnChemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-8763-6735
Andrew C AkinLos Alamos National Laboratory, Los Alamos, NM, USA.ORCID http://orcid.org/0000-0001-5013-2368
Eva R BirnbaumLos Alamos National Laboratory, Los Alamos, NM, USA.ORCID http://orcid.org/0000-0003-3334-8153
Mark BrughLos Alamos National Laboratory, Los Alamos, NM, USA.
Jason C CooleyLos Alamos National Laboratory, Los Alamos, NM, USA.
Jonathan W EngleDepartment of Medical Physics, University of Wisconsin, Madison, WI, USA.ORCID http://orcid.org/0000-0002-3399-7228
Michael E FassbenderLos Alamos National Laboratory, Los Alamos, NM, USA.ORCID http://orcid.org/0000-0003-3784-0276
Stacey S GaunyChemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
Andrew L LakesChemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
Francois M NortierLos Alamos National Laboratory, Los Alamos, NM, USA.
Ellen M O'BrienLos Alamos National Laboratory, Los Alamos, NM, USA.ORCID http://orcid.org/0000-0001-7595-1538
Sara L ThiemannLos Alamos National Laboratory, Los Alamos, NM, USA.
Frankie D WhiteLos Alamos National Laboratory, Los Alamos, NM, USA.
Christiaan VermeulenLos Alamos National Laboratory, Los Alamos, NM, USA. etienne@lanl.gov.ORCID http://orcid.org/0000-0002-6723-8983
Stosh A KozimorLos Alamos National Laboratory, Los Alamos, NM, USA. stosh@lanl.gov.ORCID http://orcid.org/0000-0001-7387-0507
Rebecca J AbergelDepartment of Nuclear Engineering, University of California, Berkeley, CA, USA. abergel@berkeley.edu.ORCID http://orcid.org/0000-0002-3906-8761
Los Alamos National Laboratory · USLawrence Berkeley National Laboratory · USUniversity of Wisconsin–Madison · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Developing targeted α-therapies has the potential to transform how diseases are treated. In these interventions, targeting vectors are labelled with α-emitting radioisotopes that deliver destructive radiation discretely to diseased cells while simultaneously sparing the surrounding healthy tissue. Widespread implementation requires advances in non-invasive imaging technologies that rapidly assay therapeutics. Towards this end, positron emission tomography (PET) imaging has emerged as one of the most informative diagnostic techniques. Unfortunately, many promising α-emitting isotopes such as

Indexed as

Positron-Emission TomographyAbdomenAnimalsCeriumCerium RadioisotopesLanthanumOxidation-ReductionRadiopharmaceuticalsTissue DistributionCeriumCerium RadioisotopesLanthanumRadiopharmaceuticals

Identifiers

PMID33318671
OpenAlexW3112419202

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.